Goldman Sachs analyst Andrea Newkirk resumes coverage on Kymera Therapeutics (NASDAQ: KYMR) with a Early-Stage Biotech rating.The analyst comments "KYMR ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage